Yi Zhao
17 articles listing Yi Zhao in Nature Communications, Science Advances, PNAS, Science, indexed by Paperzzz from Crossref and OSF.
- Gut microbiota-activated PLCγ2 monocytes drive atrial fibrillation Nature Communications
- Near-infrared-active Nd–BiO2-x/MIL-101(Fe) with vacancy-induced interfaces for solar water purification Nature Communications
- Westerly induced precipitation increase drives near-surface ground ice gain on the Tibetan Plateau despite warming Science Advances
- A high-dexterity soft neuroprosthetic hand for daily activities Nature Communications
- Spatially coupled CO2 activation and hydrogenation sites in 1 T′-MoS2 enable near-unity methanol selectivity Nature Communications
- HOP2–MND1 chaperones a diffusing DMC1–ssDNA complex to survey dsDNA for homology recognition during meiotic recombination PNAS
- Bioinspired flexible sensing-processing-visualizing integrated system towards tactile-visual signal recognition Nature Communications
- Chinese Immune Multi-Omics Atlas Science
- Deep learning-assisted discovery of a potent and cell-active inhibitor of RNA N6-methyladenosine recognition protein YTHDC2 Nature Communications
- Self-growth of programmable 2D- and 3D-coupling responsive coating for anti-counterfeiting Nature Communications
- Human alterations to global riverine phosphorus fluxes to the ocean Science Advances
- A rapid self-healing polymer mediated by ion aggregates achieves effective encapsulation of sustainable perovskite solar cells Science Advances
- LINS: A general medical Q&A framework for enhancing the quality and credibility of LLM-generated responses Nature Communications
- A magneto-responsive nanomesh biosensor for simultaneous mechanical stimulation and electrochemical detection Nature Communications
- Single-nuclei multiomics analysis identifies abnormal cardiomyocytes in a murine model of cardiac development Nature Communications
- A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis Nature Communications
- Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial Nature Communications